Anti-CD40 AAV Redosing Strategy for Host Antibody Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
In AAV gene therapies, seronegative/naive patients develop neutralizing antibody responses to the AAV capsid antigen, preventing future re-dosing due to sustained antibody responses lasting over 10 years.
Innovation Solution
Administering a nucleic acid construct encoding a polypeptide of interest, a nuclease agent targeting a specific genomic locus, and a CD40 inhibitor (e.g., CD40 antigen-binding molecule) to cleave the target site, allowing insertion and expression of the polypeptide at the genomic locus, thereby treating enzyme deficiencies and preventing symptom onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV gene therapy is administered to seronegative/naive patients, then the polypeptide of interest is expressed to treat enzyme deficiency, but neutralizing antibody responses develop that prevent future re-dosing
Solution Approach 1:
The patent applies preliminary action by administering the CD40 inhibitor before the AAV gene therapy to pre-suppress the host antibody response. This preventive measure ensures that neutralizing antibodies are blocked before they can form, enabling subsequent re-dosing of AAV therapy without immune interference.
Solution Approach 2:
The CD40 inhibitor serves as an intermediary substance that mediates between the AAV capsid antigen and the host immune system. By blocking CD40 signaling, it prevents the formation of neutralizing antibodies, thus enabling repeated administration of AAV therapy without immunological barriers.
2Productivity
If AAV capsid antigen is introduced, then gene therapy effect is achieved, but sustained neutralizing antibody response lasts 10+ years preventing repeat dosing
Solution Approach 1:
The CD40 inhibitor is administered in advance to pre-establish immune suppression before AAV capsid antigen exposure. This timing strategy ensures that the inhibitor is active during the critical window when neutralizing antibodies would otherwise form and persist for over 10 years, thereby enabling repeat dosing.
Solution Approach 2:
The patent changes the immunological parameter by using the CD40 inhibitor to alter the host's antibody response characteristics. This modification transforms the sustained neutralizing response into a suppressed state, allowing repeated AAV administration without the usual long-term immune barriers.
3Adaptability or versatility
If CD40 inhibitor is administered with nucleic acid construct and nuclease agent, then repeated AAV dosing is enabled, but treatment complexity increases
Solution Approach 1:
The patent merges the CD40 inhibitor administration with the nucleic acid construct and nuclease agent delivery in a single integrated treatment protocol. By combining these components into one coordinated intervention, the complexity of managing separate treatments is reduced while maintaining the ability to enable repeated AAV dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables repeated dosing of AAV therapies by suppressing host antibody responses, achieving desired polypeptide expression levels over time, particularly for conditions like hemophilia B and Pompe disease.
Implementation Method 1
Administering a nucleic acid construct encoding a polypeptide of interest, a nuclease agent targeting a specific genomic locus, and a CD40 inhibitor (e.g., CD40 antigen-binding molecule)
Implementation Method 2
a nuclease agent or one or more nucleic acids encoding the nuclease agent, wherein the nuclease agent targets a nuclease target site in the target genomic locus... the nuclease agent cleaves the nuclease target site
Data Source
AI summary
Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. The methods use CD40 inhibitors (e.g., CD40 antigen-binding molecules) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.